Fulgent Genetics (NASDAQ: FLGT) revenue
Fulgent Genetics reported revenue of $322.7m for fiscal 2025, 13.8% more than in fiscal 2024 ($283.5m). Since fiscal 2016 its revenue has grown by 1,665.5%, an average growth of 37.6% a year.
Fulgent Genetics's best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2023, −53.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $322.7m | +13.8% | −$91.1m | −28.2% |
| 2024 | $283.5m | −2.0% | −$73.9m | −26.1% |
| 2023 | $289.2m | −53.3% | −$195.5m | −67.6% |
| 2022 | $619.0m | −37.6% | $178.5m | 28.8% |
| 2021 | $992.6m | +135.4% | $676.0m | 68.1% |
| 2020 | $421.7m | +1,196.5% | $290.2m | 68.8% |
| 2019 | $32.5m | +52.3% | −$0.4m | −1.3% |
| 2018 | $21.4m | +14.0% | −$5.1m | −23.7% |
| 2017 | $18.7m | +2.5% | −$3.5m | −18.6% |
| 2016 | $18.3m | — | $0.9m | 5.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Fulgent Genetics revenue compared with its sector
By revenue for its latest fiscal year, Fulgent Genetics ranks 215th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Fulgent Genetics, 13.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 213th | Castle Biosciences | $344.2m | 3.7% |
| 214th | Tactile Systems Technology | $329.5m | 12.5% |
| 215th | Fulgent Genetics | $322.7m | 13.8% |
| 216th | AngioDynamics | $320.2m | 9.5% |
| 217th | Cormedix | $311.7m | 617.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Fulgent Genetics
- How much revenue did Fulgent Genetics make in fiscal 2025?
- Fulgent Genetics reported revenue of $322.7m for fiscal 2025, compared with $283.5m in fiscal 2024.
- How much has the revenue of Fulgent Genetics grown?
- Between fiscal 2016 and fiscal 2025 it went from $18.3m to $322.7m: 1,665.5% more, an average growth of 37.6% a year.
- What was the best year for revenue at Fulgent Genetics?
- Of its last 10 fiscal years, fiscal 2021, with $992.6m.
- Where does Fulgent Genetics rank in its sector by revenue?
- It ranks 215th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Fulgent Genetics come from?
- From the annual report (Form 10-K) that Fulgent Genetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Fulgent Genetics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Fulgent Genetics: the Fulgent Genetics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.